Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 6/2024

22-03-2024 | Scintigraphy | Original Article

Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment

Authors: Shohei Fukai, Hiromitsu Daisaki, Takuro Umeda, Naoki Shimada, Takashi Terauchi, Mitsuru Koizumi

Published in: Annals of Nuclear Medicine | Issue 6/2024

Login to get access

Abstract

Objective

Radium-223 is a first alpha-emitting radionuclide treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with bone metastases. Although the spread-based bone scan index (BSI) and novel index of the intensity-based two-dimensional total bone uptake (2D-TBU) from bone scintigraphy may provide useful input in radium-223 treatment, they have not been evaluated in detail yet. This study aimed to fill this gap by evaluating BSI and 2D-TBU in patients treated with radium-223.

Methods

Twenty-seven Japanese patients with mCRPC treated with radium-223 were retrospectively analyzed. The patients were evaluated via blood tests and bone scans at baseline and 3 cycles intervals of treatment. BSI and 2D-TBU were analyzed via VSBONE BSI in terms of correlations, response to radium-223 treatment, association with treatment completion, and the Kaplan–Meier survival analysis was performed.

Results

Nineteen patients (70.4%) completed six cycles of radium-223 treatment, whereas eight patients (29.6%) did not complete the treatment regimen. A significant difference in baseline BSI and 2D-TBU was observed between these groups of patients. Both BSI and 2D-TBU were highly correlated (r = 0.96, p < 0.001). Univariate analysis showed an association between radium-223 completion in median BSI and 2D-TBU values (p = 0.015) and completion percentage differences (91.7% vs. 45.5%; p = 0.027). The Kaplan–Meier product limit estimator showed that the median overall survival was 25.2 months (95% CI 14.0–33.6 months) in the completion group and 7.5 months (95% CI 3.3–14.2 months) in the without completion group (p < 0.001). The overall survival based on median cutoff levels showed a significant difference in 2D-TBU (p = 0.007), but not in BSI (p = 0.15).

Conclusions

The 2D-TBU may offer advantages over BSI in classifying patients towards radium-223 treatment based on the degree of progression of bone metastases. This study supports the importance of preliminary assessment of bone metastasis status using BSI and 2D-TBU extracted from VSBONE BSI for radium-223 treatment decisions.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65(2):270–3.PubMedCrossRef
3.
Nishimura K. Management of bone metastasis in prostate cancer. J Bone Miner Metab. 2023;41(3):317–26.PubMedCrossRef
4.
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.PubMedCrossRef
5.
van der Zande K, Oyen WJG, Zwart W, Bergman AM. Radium-223 treatment of patients with metastatic castration resistant prostate cancer: biomarkers for stratification and response evaluation. Cancers. 2021;13(17):4346.PubMedPubMedCentralCrossRef
6.
Miyoshi Y, Tsutsumi S, Yasui M, Kawahara T, Uemura KI, Hayashi N, et al. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer. World J Urol. 2021;39(9):3323–8.PubMedPubMedCentralCrossRef
7.
Takeda K, Kawasaki Y, Sakayauchi T, Takahashi C, Katagiri Y, Tanabe T, et al. Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer. Asia Ocean J Nucl Med Biol. 2023;11(1):13–22.PubMedPubMedCentral
8.
Ito H, Yaegashi H, Okada Y, Shimada T, Yamaoka T, Okubo K, et al. Risk scoring system for Ra-223 discontinuation and its effect on prognosis: a retrospective study. Cancer Diagn Progn. 2021;1(4):323–30.PubMedPubMedCentralCrossRef
9.
Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res. 1998;4(7):1765–72.PubMed
10.
Nakajima K, Edenbrandt L, Mizokami A. Bone scan index: a new biomarker of bone metastasis in patients with prostate cancer. Int J Urol. 2017;24(9):668–73.PubMedCrossRef
11.
Nakajima K, Mizokami A, Matsuyama H, Ichikawa T, Kaneko G, Takahashi S, et al. Prognosis of patients with prostate cancer and bone metastasis from the Japanese prostatic cancer registry of standard hormonal and chemotherapy using bone scan index cohort study. Int J Urol. 2021;28(9):955–63.PubMedPubMedCentralCrossRef
12.
Yoshida A, Higashiyama S, Kawabe J. Predicting the prognosis of prostate cancer bone metastasis using the bone scan index and hot spots calculated using VSBONEⓇ bone scan index from Tc-99m-HYdroxymethylene diphosphonate bone scintigraphy. Urol Int. 2022;106(9):963–9.PubMedCrossRef
13.
Umeda T, Koizumi M, Fukai S, Miyaji N, Motegi K, Nakazawa S, et al. Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients. Ann Nucl Med. 2018;32(2):105–13.PubMedCrossRef
14.
Brix G, Nekolla EA, Borowski M, Noßke D. Radiation risk and protection of patients in clinical SPECT/CT. Eur J Nucl Med Mol Imaging. 2014;41(Suppl 1):S125–36.PubMedCrossRef
15.
Zacho HD, Manresa JAB, Aleksyniene R, Ejlersen JA, Fledelius J, Bertelsen H, et al. Three-minute SPECT/CT is sufficient for the assessment of bone metastasis as add-on to planar bone scintigraphy: prospective head-to-head comparison to 11-min SPECT/CT. EJNMMI Res. 2017;7(1):1.PubMedPubMedCentralCrossRef
16.
Shimizu A, Wakabayashi H, Kanamori T, Saito A, Nishikawa K, Daisaki H, et al. Automated measurement of bone scan index from a whole-body bone scintigram. Int J Comput Assist Radiol Surg. 2020;15(3):389–400.PubMedCrossRef
17.
Erdi YE, Humm JL, Imbriaco M, Yeung H, Larson SM. Quantitative bone metastases analysis based on image segmentation. J Nucl Med. 1997;38(9):1401–6.PubMed
18.
Shintawati R, Achmad A, Higuchi T, Shimada H, Hirasawa H, Arisaka Y, et al. Evaluation of bone scan index change over time on automated calculation in bone scintigraphy. Ann Nucl Med. 2015;29(10):911–20.PubMedCrossRef
19.
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.PubMedCrossRef
20.
Saad F, Gillessen S, Heinrich D, Keizman D, O’Sullivan JM, Nilsson S, et al. Disease characteristics and completion of treatment in patients with metastatic castration-resistant prostate cancer treated with Radium-223 in an international early access program. Clin Genitourin Cancer. 2019;17(5):348-355.e5.PubMedCrossRef
21.
22.
Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28:1090.PubMedPubMedCentralCrossRef
23.
Kawaguchi G, Akazawa K, Ikeda T, Ikeda Y, Hara N, Nishiyama T. Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer. SAGE Open Med. 2023;11:20503121231168492.PubMedPubMedCentralCrossRef
24.
Matsumoto T, Hori Y, Shiota M, Blas L, Nakamura M, Seki N, et al. Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: a multi-institutional study. Int J Urol. 2023;30(2):139–46.PubMedCrossRef
25.
Kawahara T, Miyoshi Y, Ninomiya S, Sato M, Takeshima T, Hasumi H, et al. Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: a large database study. Int J Urol. 2022;29(9):1079–84.PubMedPubMedCentralCrossRef
26.
Miyoshi Y, Tsutsumi S, Kawahara T, Yasui M, Uemura K, Yoneyama S, et al. Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium-223. BJUI Compass. 2020;2(1):24–30.PubMedPubMedCentralCrossRef
27.
Shariftabrizi A, Kothari S, George S, Attwood K, Levine E, Lamonica D. Optimization of Radium-223 treatment of castration-resistant prostate cancer based on the burden of skeletal metastasis and clinical parameters. Oncologist. 2023;28(3):246–51.PubMedPubMedCentralCrossRef
28.
Naito M, Ukai R, Hashimoto K. Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223. Cancer Rep. 2019;2(5): e1203.CrossRef
29.
Kitajima K, Igeta M, Kuyama J, Kawahara T, Suga T, Otani T, et al. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 therapy in prostate cancer using bone scan index (J-RAP-BSI) trial. Eur J Nucl Med Mol Imaging. 2023;50(5):1487–98.PubMedCrossRef
30.
Ichikawa H, Shibutani T, Onoguchi M, Taniguchi Y. New index to assess the extent of bone disease in patients with prostate cancer using SPECT/CT. Ann Nucl Med. 2022;36(11):941–50.PubMedCrossRef
31.
Dittmann H, Kaltenbach S, Weissinger M, Fiz F, Martus P, Pritzkow M, et al. The prognostic value of quantitative bone SPECT/CT before 223Ra treatment in metastatic castration-resistant prostate cancer. J Nucl Med. 2021;62(1):48–54.PubMedCrossRef
32.
Oya T, Ichikawa Y, Nakamura S, Tomita Y, Sasaki T, Inoue T, et al. Quantitative assessment of 99mTc-methylene diphosphonate bone SPECT/CT for assessing bone metastatic burden and its prognostic value in patients with castration-resistant prostate cancers: initial results in a single-center retrospective study. Ann Nucl Med. 2023;37(6):360–70.PubMedCrossRef
33.
Matsubara N, Nagamori S, Wakumoto Y, Uemura H, Kimura G, Yokomizo A, et al. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer. Int J Clin Oncol. 2018;23(1):173–80.PubMedCrossRef
34.
Uemura H, Uemura H, Matsubara N, Kinuya S, Hosono M, Yajima Y, et al. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases. Int J Clin Oncol. 2017;22(5):954–63.PubMedPubMedCentralCrossRef
35.
Nome R, Hernes E, Bogsrud TV, Bjøro T, Fosså SD. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. Scand J Urol. 2015;49(3):211–7.PubMedCrossRef
36.
Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, et al. Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(7):944–51.PubMedPubMedCentralCrossRef
37.
Hashimoto K, Miyoshi Y, Shindo T, Hori M, Tsuboi Y, Kobayashi K, et al. Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer. Cancer Med. 2020;9(22):8579–88.PubMedPubMedCentralCrossRef
38.
Kaneta T, Ogawa M, Daisaki H, Nawata S, Yoshida K, Inoue T. SUV measurement of normal vertebrae using SPECT/CT with Tc-99m methylene diphosphonate. Am J Nucl Med Mol Imaging. 2016;6(5):262–8.PubMedPubMedCentral
39.
Fukai S, Daisaki H, Umeda T, Shimada N, Miyaji N, Ito R, et al. Impact of patient body habitus on image quality and quantitative value in bone SPECT/CT. Ann Nucl Med. 2022;36(6):586–95.PubMedCrossRef
40.
Motegi K, Miyaji N, Yamashita K, Koizumi M, Terauchi T. Comparison of skeletal segmentation by deep learning-based and atlas-based segmentation in prostate cancer patients. Ann Nucl Med. 2022;36(9):834–41.PubMedCrossRef
41.
Aoki Y, Nakayama M, Nomura K, Tomita Y, Nakajima K, Yamashina M, et al. The utility of a deep learning-based algorithm for bone scintigraphy in patient with prostate cancer. Ann Nucl Med. 2020;34(12):926–31.PubMedCrossRef
Metadata
Title
Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment
Authors
Shohei Fukai
Hiromitsu Daisaki
Takuro Umeda
Naoki Shimada
Takashi Terauchi
Mitsuru Koizumi
Publication date
22-03-2024
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine / Issue 6/2024
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-024-01918-4

Other articles of this Issue 6/2024

Annals of Nuclear Medicine 6/2024 Go to the issue

Original Article

18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer

Original Article

Prognostic value of left ventricular mechanical dyssynchrony indices derived from gated myocardial perfusion SPECT in coronary artery disease: a systematic review and meta-analysis

Original Article

Examination of iatrogenic FDG accumulation after COVID-19 vaccination

Original Article

Comparison of consistency in centiloid scale among different analytical methods in amyloid PET: the CapAIBL, VIZCalc, and Amyquant methods

Original Article

Quantitative analysis of abdominal aortic blood flow by 99mTc-DTPA renal scintigraphy in patients with heart failure

Original Article

Novel indices representing heterogeneous distributions of myocardial perfusion imaging